Patents by Inventor Lina Xu
Lina Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150455Abstract: Provided are an anti-CLDN6 antibody or an antigen-binding fragment thereof; a nucleic acid molecule encoding same; an immunoconjugate, a bispecific molecule, a chimeric antigen receptor and a pharmaceutical composition containing same; and the use thereof for preventing and/or treating tumors.Type: ApplicationFiled: March 5, 2021Publication date: May 9, 2024Inventors: Liang Du, Hongyan Zhang, Lina Jin, Yali Chen, Tingting Wan, Liuliu Xu, Jijun Yuan
-
Publication number: 20240131017Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: ApplicationFiled: December 29, 2023Publication date: April 25, 2024Applicant: Techfields Pharma Co., Ltd.Inventors: Chongxi Yu, Lina Xu
-
Patent number: 11965037Abstract: Provided is an anti-HER3 humanized monoclonal antibody. The antibody binds HER3 antigen, has high affinity and biological activity and low immunogenicity, and is stable in structure. The antibody can be used for preparing drugs for preventing or treating HER3-related diseases.Type: GrantFiled: July 17, 2019Date of Patent: April 23, 2024Assignee: SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.Inventors: Aidong Qu, Hongyuan Liang, Fanhong Xu, Aoxiang Li, Lina Wu, Jingye Zhu, Jianhua Qiu, Jin Lu, Lin Zhang, Xin Zhao, Xiaofei Song
-
Publication number: 20240115562Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: ApplicationFiled: November 13, 2023Publication date: April 11, 2024Applicant: Techfields Pharma Co., Ltd.Inventors: Chongxi Yu, Lina Xu
-
Publication number: 20240068919Abstract: A rock direct tensile test platform suitable for all material test machines includes a support frame. A top of the support frame is fixed with a top plate, and a bearing plate is provided above the top plate. The bearing plate is provided with a plurality of vertical force transferring rods. The force transferring rods vertically penetrate through the top plate and have a sliding fit with the top plate. Lower ends of the force transferring rods are provided with a tensile base. A top of the tensile base is provided with a lower clamp holder. A bottom of the top plate is provided with an upper clamp holder, and a clamp center of the upper clamp holder coincides with a clamp center of the lower clamp holder.Type: ApplicationFiled: September 11, 2023Publication date: February 29, 2024Inventors: Jianfeng LIU, Heping XIE, Lu WANG, Yougang CAI, Lina RAN, Chunping WANG, Gan FENG, Hua LI, Xiangchao SHI, Jianliang PEI, Huining XU, Xiaozhang LEI, Jianhui DENG
-
Publication number: 20240068917Abstract: An integrated acoustic detection and rock direct tensile test machine includes a support frame. A top of the support frame is provided with a top plate and a bearing plate is provided above the top plate. The bearing plate is provided with force transferring rods, lower ends of which are provided with a tensile base. A top of the tensile base is provided with a lower clamp holder and a bottom of the top plate is provided with an upper clamp holder. An upper channel is provided inside the upper clamp holder. The upper channel is provided with an acoustic transmitting probe. A lower channel is provided inside the lower clamp holder. One end of the lower channel is communicated with the outside, the other end is provided with an acoustic receiving probe. The lower channel extends to a bottom of a clamping chamber of the lower clamp holder.Type: ApplicationFiled: August 24, 2023Publication date: February 29, 2024Inventors: Huining XU, Tianqi LIU, Jianfeng LIU, Fujun XUE, Jingjing DAI, Lu WANG, Lina RAN, Yougang CAI, Jianliang PEI, Hua LI, Jinbing WEI, Jianhui DENG
-
Publication number: 20240024273Abstract: Provided herein is 2-(diethylamino) ethyl 2-(4-isobutylphenyl) propionate or pharmaceutically acceptable salts thereof. Furthermore, for use and methods in the treatment of various pains and inflammation, in particular osteoarthritis with pharmaceutical compositions, treatment kits and devices comprising 2-(diethylamino) ethyl 2-(4-isobutylphenyl) propionate and/or pharmaceutically acceptable salts thereof, as well as dosage forms, dosages, and methods of use thereof through topical administration, for treatment of various pains and inflammation, in particular osteoarthritis, are disclosed.Type: ApplicationFiled: June 4, 2021Publication date: January 25, 2024Inventors: Chongxi Yu, Lina Xu
-
Patent number: 11857545Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: GrantFiled: November 14, 2014Date of Patent: January 2, 2024Assignee: Techfields Pharma Co., Ltd.Inventors: Chongxi Yu, Lina Xu
-
Patent number: 11813256Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: GrantFiled: January 16, 2019Date of Patent: November 14, 2023Inventors: Chongxi Yu, Lina Xu
-
Patent number: 11685739Abstract: One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: GrantFiled: August 9, 2021Date of Patent: June 27, 2023Assignee: TECHFIELDS PHARMA CO., LTD.Inventors: Chongxi Yu, Lina Xu
-
Patent number: 11685778Abstract: Disclosed in the present invention are an antibody targeting LAG-3, a preparation method therefor and the use thereof. In particular, disclosed in the present invention is a novel monoclonal antibody targeting LAG-3. Also disclosed in the present invention is a method for the preparation of the monoclonal antibody. The monoclonal antibody of the present invention is capable of binding LAG-3 antigens with high specificity, and has very high affinity and significant activities such as anti-tumor activity.Type: GrantFiled: April 2, 2019Date of Patent: June 27, 2023Assignee: JIANGSU HUAIYU PHARMACEUTICAL CO., LTD.Inventors: Ningning Song, Qing Duan, Xiaohui Shao, Peng Wang, Xiaojiao Bian, Qian Wang, Peipei Wei, Yajun Huang, Jian Wu, Meiling Wang, Yuandong Wang, Lina Xu, Tatchi Teddy Yang, Lile Liu
-
Publication number: 20230174476Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of prostaglandins which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: ApplicationFiled: January 16, 2023Publication date: June 8, 2023Applicant: TECHFIELDS PHARMA CO., LTD.Inventors: Chongxi Yu, Lina Xu
-
Publication number: 20230157952Abstract: Provided are pharmaceutical compositions comprising at least one high penetration drug (HPD) that has at least one protonated amino group in its molecular and is capable of penetrating across one or more biological barriers in high rates, methods for improving the stability of the pharmaceutical compositions, and methods of using the pharmaceutical compositions for preventing, diagnosing and/or treating condition or disease in human, animals and plants.Type: ApplicationFiled: March 22, 2021Publication date: May 25, 2023Applicant: Techfields Inc.Inventors: Chongxi Yu, Lina Xu
-
Publication number: 20230130980Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: ApplicationFiled: October 31, 2022Publication date: April 27, 2023Applicant: TECHFIELDS PHARMA CO., LTD.Inventors: Chongxi Yu, Lina Xu, Yuhua Chen, Binbing Yan, Shiqian Tu
-
Patent number: 11624688Abstract: Disclosed is a testing device for measuring interfacial shear properties between fibers and media, including a main body, which is a rectangular plate-like structure with L-shaped plates provided at the bottom ends of the main body, a connecting rod provided at a top right of the main body, a groove provided at the top of the main body; and four rotating grooves are provided inside the groove. The rotating grooves are cylindrical structures with raised centers at both ends; and a mounting piece is installed above the left end of the main body; a magnet of a displacement micrometer is connected to a tension trolley, a high-definition camera is turned on, weights are added into a loading bucket and the fiber movement is observed until the fiber is pulled out or sliding friction occurs, and then the camera is stopped and accurate data is tested.Type: GrantFiled: August 16, 2022Date of Patent: April 11, 2023Assignee: Jilin Jianzhu UniversityInventors: Lina Xu, Lei Niu, Yujie Jin, Yongmei Qian, Wei Tian, Ning Liu
-
Publication number: 20230097823Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of mustards and mustard-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: ApplicationFiled: October 24, 2022Publication date: March 30, 2023Applicant: TECHFIELDS PHARMA CO., LTDInventors: Chongxi Yu, Lina Xu
-
Patent number: 11612165Abstract: Disclosed is a pesticide composition for controlling Spodoptera frugiperda. The pesticide includes an auxiliary material, an active ingredient A and an active ingredient B. The active ingredient A is tea saponin, the active ingredient B is chlorantraniliprole or tolfenpyrad, and the mass ratio of the active ingredient A to the active ingredient B is 1-20:20-1. In the present invention, by mixing tea saponin with chlorantraniliprole or tolfenpyrad, a pesticide with certain ratio is prepared to control Spodoptera frugiperda, has the advantages of good effect and low dosage, and can delay the resistance of Spodoptera frugiperda to pesticides.Type: GrantFiled: September 29, 2020Date of Patent: March 28, 2023Assignee: INSTITUTE OF PROTECTION AND AGRO-PRODUCTS SAFETY, ANHUI ACADEMY OF AGRICULTURAL SCIENCEInventors: Xuexiang Ren, Zhenghe Ye, Xianyan Su, Lina Xu, Haoliang Chen, Yu Chi
-
Publication number: 20230058391Abstract: Disclosed is a testing device for measuring interfacial shear properties between fibers and media, including a main body, which is a rectangular plate-like structure with L-shaped plates provided at the bottom ends of the main body, a connecting rod provided at a top right of the main body, a groove provided at the top of the main body; and four rotating grooves are provided inside the groove. The rotating grooves are cylindrical structures with raised centers at both ends; and a mounting piece is installed above the left end of the main body; a magnet of a displacement micrometer is connected to a tension trolley, a high-definition camera is turned on, weights are added into a loading bucket and the fiber movement is observed until the fiber is pulled out or sliding friction occurs, and then the camera is stopped and accurate data is tested.Type: ApplicationFiled: August 16, 2022Publication date: February 23, 2023Applicant: Jilin Jianzhu UniversityInventors: Lina XU, Lei NIU, Yujie JIN, Yongmei QIAN, Wei TIAN, Ning LIU
-
Patent number: 11555014Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of prostaglandins or prostaglandin analogs which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent prostaglandins or prostaglandin analogs after crossing the biological barrier and thus can render treatments for the conditions that the parent prostaglandins or prostaglandin analogs can. Additionally, the HPPs are capable of reaching areas that parent prostaglandins or prostaglandin analogs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: GrantFiled: April 2, 2009Date of Patent: January 17, 2023Assignee: Techfields Pharma Co., Ltd.Inventors: Chongxi Yu, Lina Xu
-
Patent number: 11485744Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: GrantFiled: April 9, 2018Date of Patent: November 1, 2022Assignee: Techfields Pharma Co., Ltd.Inventors: Chongxi Yu, Lina Xu, Yuhua Chen, Binbing Yan, Shiqian Tu